ICDcodes.org
FY2027

E72.530Primary hyperoxaluria, type 1

BillableCC

Is E72.530 billable?

Yes — E72.530 is billable for FY2027. E72.530 is a valid, billable ICD-10-CM code at the highest level of specificity in its branch. E72.530 may be submitted for encounters from October 1, 2026 through September 30, 2027.

E72.530 at a glance

CodeE72.530
DescriptionPrimary hyperoxaluria, type 1
BillableYes
Code setICD-10-CM FY2027
Valid for encountersOctober 1, 2026 – September 30, 2027

Which MS-DRGs does E72.530 group to?

E72.530 sits in MDC 10 and helps define the logic of 1 MS-DRG (version 44, FY2027). Which one a stay actually groups to also depends on procedures and secondary diagnoses.

  • 642Inborn and Other Disorders of Metabolismmedical

As a secondary diagnosis, E72.530 is a complication or comorbidity (CC), which can move a stay into a higher-paying DRG.

How is E72.530 listed in the Alphabetic Index?

These are the routes through the Alphabetic Index that lead to E72.530. They show the wording a clinician may have documented, which often differs from the Tabular description.

  • Disorderglycine metabolismhyperoxaluriaprimarytype 1 (of)

Excludes1 — never code together — inherited from Chapter 4

The conditions below can never be reported together with E72.530 on the same claim. An Excludes1 note means the two conditions cannot occur in the same patient, so reporting both is a coding error.

  • transitory endocrine and metabolic disorders specific to newborn (P70-P74)

Excludes1 — never code together — inherited from E70-E88

The conditions below can never be reported together with E72.530 on the same claim. An Excludes1 note means the two conditions cannot occur in the same patient, so reporting both is a coding error.

  • androgen insensitivity syndrome (E34.5-)
  • congenital adrenal hyperplasia (E25.0)
  • hemolytic anemias attributable to enzyme disorders (D55.-)
  • Marfan syndrome (Q87.4-)
  • 5-alpha-reductase deficiency (E29.1)

Excludes1 — never code together — inherited from E72

The conditions below can never be reported together with E72.530 on the same claim. An Excludes1 note means the two conditions cannot occur in the same patient, so reporting both is a coding error.

  • disorders of:
  • aromatic amino-acid metabolism (E70.-)
  • branched-chain amino-acid metabolism (E71.0-E71.2)
  • fatty-acid metabolism (E71.3)
  • purine and pyrimidine metabolism (E79.-)
  • gout (M1A.-, M10.-)

Excludes1 — never code together — inherited from E72.53

The conditions below can never be reported together with E72.530 on the same claim. An Excludes1 note means the two conditions cannot occur in the same patient, so reporting both is a coding error.

Excludes2 — not included here — inherited from E70-E88

The conditions below are not part of E72.530, but a patient may have both at the same time. When documentation supports it, E72.530 and the excluded code may both be reported.

  • Ehlers-Danlos syndromes (Q79.6-)

How long has E72.530 existed?

E72.530 first appears in FY2026.

Derived from the official order files for FY2016–FY2026. FY2017 and FY2020 publish no order file, so those years are not covered.

What other codes are in the E72.53 family? (2)